Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD
5.64
+0.27 (5.03%)
At close: Apr 23, 2024, 4:00 PM
5.51
-0.13 (-2.30%)
After-hours: Apr 23, 2024, 5:20 PM EDT
Sight Sciences Market Cap
Sight Sciences has a market cap or net worth of $279.48 million as of April 23, 2024. Its market cap has decreased by -37.12% in one year.
Market Cap
279.48M
Enterprise Value
175.28M
1-Year Change
-37.12%
Ranking
Category
Stock Price
$5.64
Market Cap Chart
Since the IPO on July 15, 2021, Sight Sciences's market cap has decreased from $1.08B to $279.48M, a decrease of -74.16%. That is a compound annual growth rate of -38.62%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 22, 2024 | 266.10M | 4.68% |
Apr 19, 2024 | 254.20M | -2.12% |
Apr 18, 2024 | 259.70M | -2.59% |
Apr 17, 2024 | 266.60M | 2.85% |
Apr 16, 2024 | 259.20M | -5.40% |
Apr 15, 2024 | 274.00M | -4.83% |
Apr 12, 2024 | 287.90M | -4.76% |
Apr 11, 2024 | 302.30M | 2.86% |
Apr 10, 2024 | 293.90M | -2.29% |
Apr 9, 2024 | 300.80M | 12.41% |
Apr 8, 2024 | 267.60M | -2.69% |
Apr 5, 2024 | 275.00M | -0.54% |
Apr 4, 2024 | 276.50M | 6.67% |
Apr 3, 2024 | 259.20M | -3.86% |
Apr 2, 2024 | 269.60M | 2.47% |
Apr 1, 2024 | 263.10M | 0.57% |
Mar 28, 2024 | 261.60M | 1.91% |
Mar 27, 2024 | 256.70M | 2.97% |
Mar 26, 2024 | 249.30M | 0.20% |
Mar 25, 2024 | 248.80M | -2.32% |
Mar 22, 2024 | 254.70M | - |
Mar 21, 2024 | 254.70M | -0.20% |
Mar 20, 2024 | 255.20M | 1.19% |
Mar 19, 2024 | 252.20M | 8.05% |
Mar 18, 2024 | 233.40M | 4.90% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Inozyme Pharma | 280.82M |
Nanobiotix | 279.37M |
Vanda Pharmaceuticals | 279.06M |
Invivyd | 278.98M |
Bioventus | 277.92M |
Black Diamond Therapeutics | 270.48M |
Pyxis Oncology | 270.09M |
Metagenomi | 269.80M |